Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes
Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, Joshua N. Farr, David G. Monroe, Sundeep Khosla
Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, Joshua N. Farr, David G. Monroe, Sundeep Khosla
View: Text | PDF
Research Article Aging Bone biology

Aged murine bone marrow myeloid and mesenchymal cells develop unique senescence phenotypes

  • Text
  • PDF
Abstract

Cellular senescence is a heterogeneous phenotype characterized primarily in mesenchymal cells, but the extent to which immune cells differ in their senescence phenotype, or “senotype,” is unclear. Here, we applied single-cell approaches alongside both global and cell-specific genetic senolytic mouse models to evaluate the senotype of immune cells in the bone marrow of aging mice. We found that myeloid-lineage cells exhibited the highest expression of p16 and senescence-associated secretory phenotype markers among all immune cell types. In contrast with clearance of p16+ senescent mesenchymal cells, targeted clearance of p16+ myeloid cells in aged mice had only minor effects on age-related bone loss in male mice, with no effects in females. In more detailed analyses, p16+ myeloid cells were only acutely cleared, being repopulated back to basal levels within a short time. This led to a lack of long-lasting reduction in senescent cell burden, unlike when targeting bone mesenchymal cells. In vitro, myeloid-lineage cells differed markedly from mesenchymal cells in the development of a senescent phenotype. Collectively, our findings indicate that aged bone marrow myeloid cells do not achieve the fully developed senescent phenotype originally described in mesenchymal cells, justifying further characterization of senotypes of immune cells across tissues.

Authors

Madison L. Doolittle, Mitchell N. Froemming, Jennifer L. Rowsey, Ming Ruan, Leena Sapra, Joshua N. Farr, David G. Monroe, Sundeep Khosla

×

Figure 2

Clearance of p16+ myeloid cells has limited effects on age-related bone loss in male mice with no effects in females.

Options: View larger image (or click on image) Download as PowerPoint
Clearance of p16+ myeloid cells has limited effects on age-related bone ...
(A) Schematic of the un-recombined p16-LOX-ATTAC transgene crossed with the Lyz2 (LysM)-Cre. These LysM-LOX-ATTAC mice were then aged to 24 months, and bone marrow was harvested for CyTOF analysis at 24 hours after treatment with either vehicle or AP. n = 12 mice per treatment (6 male, 6 female). (B) p16 median expression and (C) %p16+ cells quantified in myeloid cells (CD14+), B cells (CD19+), and T cells (CD3+). (D) Volcano plot of differences in senescence-associated factor expression in CD14+ cells in AP- versus vehicle-treated mice. (E) Schematic of LysM-LOX-ATTAC bone phenotyping cohort, which were treated with vehicle or AP twice weekly from 20 to 24 months old. N = 44 females (N = 22 vehicle, N = 22 AP). N = 26 males (N = 11 vehicle, N = 15 AP). (F–M) μCT analyses in female (F–I) and male (J–M) mice. Cortical thickness (Ct.Th) at the diaphysis (F and J) and metaphysis (G and K) of the femur, as well as trabecular bone volume over total volume (BV/TV) at the femur metaphysis (H and L) and lumbar spine (I and M). (N) Number of osteoclasts per bone perimeter (N.Oc/B.Pm) or (O) osteoblasts per bone perimeter (N.Ob/B.Pm) measured by histomorphometry in male mice. N = 7–10 males per treatment. Significance was determined by multiple t tests with Holm-Šídák correction (B–D) and unpaired t test or Mann-Whitney test, as appropriate (F–O).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts